1. Scrip
  2. >>Focus On Asia

Asia Deal Watch: Takeda On A Deal Spree

 
• By Ian Haydock, Jung Won Shin, and Joseph Haas

Takeda has inked three deals in recent days: a cancer antibody-drug conjugate partnership, a PI3K out-license and a nanomedicine drug-delivery pact. AstraZeneca gains expanded rights to Kyowa Hakko Kirin’s Fasenra.

KONSKIE, POLAND - JULY 21, 2018: Takeda Pharmaceutical company website displayed on a modern smartphone
Takeda Active in Deal-Making • Source: Shutterstock

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions.

In the most recent of three deals announced by Takeda Pharmaceutical Co. Ltd. over three days, LegoChem Biosciences...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip